Medication-Encoded Electromagnetic Waves as a Cardiomyogenic Cue for Human Adipose-Derived Stem Cells

This study evaluated whether medication-derived electromagnetic waves (MEMW) generated from a combination of clinically used cardiovascular drugs could produce early cardiomyogenic responses comparable to direct medication exposure in human adipose-derived stem cells (ADSCs). ADSCs were assigned to untreated control, direct-medication (salbutamol, ivabradine, valsartan, and sacubitril), or corresponding MEMW exposure groups. After 21 days, cellular morphology, crystal violet staining, and quantitative reverse-transcription PCR were assessed. Both intervention groups showed modest changes from randomly oriented fibroblast-like morphology toward more elongated and aligned arrangements. POU5F1 (OCT4), SOX2, and NANOG expression decreased, whereas the early cardiac-associated markers GATA4, NKX2-5, and NPPA increased. Changes in the late markers TNNI3 and MYH6 were smaller, indicating early cardiomyogenic commitment rather than mature cardiomyocyte differentiation. MEMW exposure therefore produced selected biological responses that broadly paralleled direct medication treatment under the conditions tested. Independent signal characterization, sham controls, protein-level validation, and functional assays are required before mechanistic or translational conclusions can be drawn.